Insulin Lispro

Insulin Lispro binds to insulin receptors on cell surfaces, activating intracellular pathways that promote the movement of glucose transporters to the cell membrane. This accelerates glucose uptake into muscle and fat cells while suppressing hepatic glucose production, leading to a swift reduction in circulating blood sugar.

The dose of Insulin Lispro is individualized. A qualified prescriber determines the appropriate amount based on the patient’s blood glucose patterns, carbohydrate intake, and overall treatment plan. Patients should follow the specific dosing instructions provided by their healthcare professional.

Data on Insulin Lispro use in pregnancy and lactation are limited. It may be used only when the expected benefit to the mother outweighs potential risks to the fetus or infant. Pregnant or nursing patients should discuss therapy with their obstetrician or endocrinologist.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Insulin Lispro has a rapid onset and short duration similar to other rapid‑acting analogs such as insulin aspart and insulin glulisine. Its molecular structure provides a slightly faster initial absorption, which may be advantageous for tight post‑prandial control, but clinical choice often depends on individual response, cost and formulary considerations.

Insulin Lispro must be refrigerated at 2‑8 °C. Keep the vial or cartridge in its original packaging, protect it from light, and avoid freezing. Once in use, it may be stored at controlled room temperature (up to 30 °C) for a limited period, as indicated on the label, but should not be shaken vigorously.

Insulin Lispro is given by subcutaneous injection, typically into the abdomen, thigh, or upper arm. It should be injected shortly before meals (usually within 15 minutes) to match the rise in blood glucose from food intake. Proper injection technique and site rotation are essential to minimize local reactions.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical attention if a severe reaction occurs.

Insulin Lispro is contraindicated in individuals with a known hypersensitivity to insulin lispro or any of its excipients. Patients with recurrent severe hypoglycemia unawareness or those unable to monitor glucose levels appropriately should avoid its use until proper supervision is established.